ABL Continues to Support Race to Find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate

GAITHERSBURG, Md. and LYON, France, April 22, 2020 /PRNewswire/ -- Advanced BioScience Laboratories (ABL), a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) for biotherapeutics, oncolytics and vaccines, a subsidiary of the French bio-industrial group Institut MA©rieux, announced today that it has signed a contract to support immunological biomarker testing of a novel prophylactic COVID-19 vaccine candidate for a confidential customer.
ABL Continues to Support Race to Find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate
During the first phase of this partnership, ABL has agreed to utilize its unique experience in biomarker analysis to characterize the immune profile of volunteers participating to a phase 1 clinical trial for the vaccine candidate against coronavirus disease (COVID-19)."Profiling host immune status is of the highest importance for deciphering immune mechanisms that will eventually yield protective responses to COVID-19 infection. We are extremely proud to support this promising vaccine candidate by leveraging our team's deep scientific expertise and our versatile technological platforms." says Dr. Christine Bain, ABL Lyon's Scientific Director.Development services will begin immediately and both parties are working diligently to advance this vaccine clinical trial as quickly as possible.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2021    »